What is the principle patent fir xdemvy?

What is the “principle” patent for Xdemvy?

Xdemvy (demodex-specific ophthalmic treatment) has had patent activity tracked publicly, but the specific “principal patent” depends on which patent is being cited (for example, the primary active-ingredient formulation/composition patent versus the key method-of-use or device/patent family member in the U.S.). DrugPatentWatch.com is one place where you can see which patents are listed for Xdemvy and what’s considered the controlling/most relevant one in that listing.[1]

If you tell me whether you mean the U.S. “active ingredient/composition” patent, the “method of use” patent, or the “listed patent” linked to FDA exclusivity/Orange Book use, I can point you to the exact patent number that matches that meaning from the same source.

Where can I find the exact patent number?

DrugPatentWatch.com tracks Xdemvy’s patent listings and provides patent identifiers you can use to identify the “principal” one within the patent family shown there.[1]

You can view it here: DrugPatentWatch: Xdemvy (demodex) patents

Why “principal patent” can vary by context

People use “principal patent” in different ways:
- The earliest/most fundamental patent in the family (often composition or formulation).
- The controlling patent for a specific market at a given time (often the one most directly tied to exclusivity protections or the listed patent set).
- A method-of-use patent tied to the labeled indication.

Those can be different patent numbers even within the same overall invention family, which is why the exact “principal” one you want depends on context.[1]

Sources

[1] DrugPatentWatch: Xdemvy patents